270 related articles for article (PubMed ID: 36027759)
41. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
[TBL] [Abstract][Full Text] [Related]
42. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
43. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
44. PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine.
Tomura N; Mizuno Y; Saginoya T
Acta Radiol; 2016 Mar; 57(3):325-32. PubMed ID: 25795702
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
46. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
47. MRI versus
Lecouvet FE; Boyadzhiev D; Collette L; Berckmans M; Michoux N; Triqueneaux P; Pasoglou V; Jamar F; Vekemans MC
Eur Radiol; 2020 Apr; 30(4):1927-1937. PubMed ID: 31844960
[TBL] [Abstract][Full Text] [Related]
48. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
49. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
[TBL] [Abstract][Full Text] [Related]
50. Whole-body MRI with diffusion-weighted imaging as an adjunct to
Willemse JRJ; Lahaye MJ; Kok NFM; Grotenhuis BA; Aalbers AGJ; Beets GL; Rijsemus C; Maas M; van Golen LW; Beets-Tan RGH; Lambregts DMJ
Colorectal Dis; 2024 Feb; 26(2):290-299. PubMed ID: 38145899
[TBL] [Abstract][Full Text] [Related]
51. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.
Lütje S; de Rooy JW; Croockewit S; Koedam E; Oyen WJ; Raymakers RA
Ann Hematol; 2009 Dec; 88(12):1161-8. PubMed ID: 19763570
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the diagnostic accuracy of diffusion-weighted and dynamic contrast-enhanced MRI with
Diez AIG; Fuster D; Morata L; Torres F; Garcia R; Poggio D; Sotes S; Del Amo M; Isern-Kebschull J; Pomes J; Soriano A; Brugnara L; Tomas X
Eur J Radiol; 2020 Nov; 132():109299. PubMed ID: 33032207
[TBL] [Abstract][Full Text] [Related]
53. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
[TBL] [Abstract][Full Text] [Related]
54. Virtual calcium-suppression in dual energy computed tomography predicts metabolic activity of focal MM lesions as determined by fluorodeoxyglucose positron-emission-tomography.
Fervers P; Glauner A; Gertz R; Täger P; Kottlors J; Maintz D; Borggrefe J
Eur J Radiol; 2021 Feb; 135():109502. PubMed ID: 33388530
[TBL] [Abstract][Full Text] [Related]
55.
Bosma SE; Vriens D; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Bloem JL
Skeletal Radiol; 2019 Nov; 48(11):1735-1746. PubMed ID: 31016339
[TBL] [Abstract][Full Text] [Related]
56. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
[TBL] [Abstract][Full Text] [Related]
57. Staging canine patients with appendicular osteosarcoma utilizing fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography compared to whole body computed tomography.
Brody A; Crooks JC; French JM; Lang LG; Randall EK; Griffin LR
Vet Comp Oncol; 2022 Sep; 20(3):541-550. PubMed ID: 35166445
[TBL] [Abstract][Full Text] [Related]
58. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
[TBL] [Abstract][Full Text] [Related]
59. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
Gómez León N; Aguado Bueno B; Herreros Pérez M; León Ramírez LF; Alegre A; Colletti PM; Rubello D; Carreras JL; Delgado Bolton RC
Clin Nucl Med; 2021 Apr; 46(4):310-322. PubMed ID: 33534256
[TBL] [Abstract][Full Text] [Related]
60. Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.
Feng Z; He D; Mao Z; Wang Z; Zhu Y; Zhang X; Wang H
Clin Nucl Med; 2016 Mar; 41(3):e130-4. PubMed ID: 26646998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
